Risk factors

Heavy reliance on federal government contracts and Department of Energy funding drives the company's risk profile. Stringent environmental regulations, operating permits, and financial assurance requirements govern all core treatment operations. Profitability depends on successfully managing fixed-price contracts and maintaining liquidity under credit covenants.

Playboy relies heavily on brand reputation and licensing, facing unique risks from adult-content associations, international exposure, and debt obligations.

Revenue heavily depends on capital spending in energy and communication infrastructure markets. International operations drive 55 percent of net sales in 2024, exposing the company to global currency and regulatory risks. Manufacturing relies on raw materials like plastic resins, steel, and aluminum.

PSQH faces significant operating losses, with net losses of $57.7 million in 2024 and $53.3 million in 2023.

Pixelworks is heavily dependent on Asian contract manufacturers and end markets, primarily generating sales outside the U.S.

Quoin Pharmaceuticals faces heavy clinical and regulatory risks with an accumulated deficit of $55.2 million and no commercial revenue. The company relies entirely on third-party manufacturers, suppliers, and clinical trial contractors for its drug candidates. Operations are governed by Israeli law, adding cross-border corporate and acquisition complexities.

RCM Technologies faces economic cyclicality impacting its engineering and healthcare staffing segments. Client disputes over engineering designs create potential liabilities up to $3.3 million. Internal control weaknesses in information technology remain a risk area.

Rallybio relies heavily on early-stage candidates RLYB212 for FNAIT and RLYB116, operating with a small team of 25 employees. The company faces significant dilution risks due to a lack of committed external funds and no commercial revenue history. Strict healthcare regulations, intellectual property hurdles, and heavy reliance on third-party manufacturers and clinical sites dominate the risk profile.

Cartesian Therapeutics faces significant clinical-stage risks, heavy reliance on internal and third-party biological manufacturing, extensive IP and patent protection dependencies, and capital-raising needs to fund operations into mid-2027.

SilverBox Corp IV is a blank check company with no prior year risks, focused on finding an initial business combination within 24 months, subject to shareholder redemptions, sponsor conflicts, and D&O insurance challenges.

SenesTech faces heavy going concern risks, relying on ongoing external capital raises to commercialize ContraPest and Evolve. The company depends heavily on single-source triptolide from China and maintains limited internal manufacturing capacity. Nasdaq listing compliance and historical operating losses dominate the financial risk profile.

Strata Critical Medical faces primary risks from its reliance on third-party aircraft operators and concentrated medical customers.